Oruka Therapeutics Inc

ORKA

Add to Watchlist

61.930USD

-1.970-3.08%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Oruka Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

93 / 382

Overall Ranking

213 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Oruka Therapeutics Inc Highlights

StrengthsRisks

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -25.97, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 56.79M shares, increasing 10.95% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 599.96K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.26.

Analyst Rating

Based on 14 analysts

Strong Buy

Current Rating

135.692

Target Price

+114.77%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Oruka Therapeutics Inc is 5.81, ranking 309 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.81

Change

0



Financials

3.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.58

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Oruka Therapeutics Inc is 6.50, ranking 253 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -25.97, which is -296.87% below the recent high of 51.13 and -27.24% above the recent low of -33.05.

Score

Industry at a Glance

Previous score

6.50

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 93/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Oruka Therapeutics Inc is 9.00, ranking 17 out of 382 in the Biotechnology & Medical Research industry. The average price target is 46.00, with a high of 63.00 and a low of 26.00.

Score

Industry at a Glance

Previous score

9.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Oruka Therapeutics Inc is 6.78, ranking 155 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 81.67 and the support level at 51.53, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.88

Change

-0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

7.24M

+28.86%

VR Adviser, LLC

4.15M

--

Fairmount Funds Management LLC

3.71M

+9.89%

BlackRock Institutional Trust Company, N.A.

2.01M

+10.05%

Viking Global Investors LP

Star Investors

2.67M

--

Deep Track Capital LP

2.65M

+38.36%

RTW Investments L.P.

1.95M

--

Commodore Capital LP

1.75M

+23.48%

Paradigm BioCapital Advisors LP

1.71M

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Oruka Therapeutics Inc. The Biotechnology & Medical Research industry's average is 3.36. The company's beta value is -0.20. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Oruka Therapeutics Inc

ORKA

6.58 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment